Literature DB >> 17407446

Activation of NADPH oxidase by transforming growth factor-beta in hepatocytes mediates up-regulation of epidermal growth factor receptor ligands through a nuclear factor-kappaB-dependent mechanism.

Miguel M Murillo1, Irene Carmona-Cuenca, Gaelle Del Castillo, Conrad Ortiz, César Roncero, Aránzazu Sánchez, Margarita Fernández, Isabel Fabregat.   

Abstract

The TGF-beta (transforming growth factor-beta) induces survival signals in foetal rat hepatocytes through transactivation of EGFR (epidermal growth factor receptor). The molecular mechanism is not completely understood, but both activation of the TACE (tumour necrosis factor alpha-converting enzyme)/ADAM17 (a disintegrin and metalloproteinase 17; one of the metalloproteases involved in shedding of the EGFR ligands) and up-regulation of TGF-alpha and HB-EGF (heparin-binding epidermal growth factor-like growth factor) appear to be involved. In the present study, we have analysed the molecular mechanisms that mediate up-regulation of the EGFR ligands by TGF-beta in foetal rat hepatocytes. The potential involvement of ROS (reactive oxygen species), an early signal induced by TGF-beta, and the existence of an amplification loop triggered by initial activation of the EGFR, have been studied. Results indicate that DPI (diphenyleneiodonium) and apocynin, two NOX (NADPH oxidase) inhibitors, and SB431542, an inhibitor of the TbetaR-I (TGF-beta receptor I), block up-regulation of EGFR ligands and Akt activation. Different members of the NOX family of genes are expressed in hepatocytes, included nox1, nox2 and nox4. TGF-beta up-regulates nox4 and increases the levels of Rac1 protein, a known regulator of both Nox1 and Nox2, in a TbetaR-I-dependent manner. TGF-beta mediates activation of the nuclear factor-kappaB pathway, which is inhibited by DPI and is required for up-regulation of TGF-alpha and HB-EGF. In contrast, EGFR activation is not required for TGF-beta-induced up-regulation of those ligands. Considering previous work that has established the role of ROS in apoptosis induced by TGF-beta in hepatocytes, the results of the present study indicate that ROS might mediate both pro- and anti-apoptotic signals in TGF-beta-treated cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17407446      PMCID: PMC1904531          DOI: 10.1042/BJ20061846

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Post-transcriptional control regulates transforming growth factor alpha in the human carcinoma KB cell line.

Authors:  G Nicolini; M Miloso; M C Moroni; L Beguinot; L Scotto
Journal:  J Biol Chem       Date:  1996-11-22       Impact factor: 5.157

2.  Perturbation of actin dynamics induces NF-kappaB activation in myelomonocytic cells through an NADPH oxidase-dependent pathway.

Authors:  Gaelle Kustermans; Jamel El Benna; Jacques Piette; Sylvie Legrand-Poels
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

Review 3.  NF-kappaB activation by reactive oxygen species: fifteen years later.

Authors:  Geoffrey Gloire; Sylvie Legrand-Poels; Jacques Piette
Journal:  Biochem Pharmacol       Date:  2006-04-27       Impact factor: 5.858

4.  The requirement of both intracellular reactive oxygen species and intracellular calcium elevation for the induction of heparin-binding EGF-like growth factor in vascular endothelial cells and smooth muscle cells.

Authors:  Y Kayanoki; S Higashiyama; K Suzuki; M Asahi; S Kawata; Y Matsuzawa; N Taniguchi
Journal:  Biochem Biophys Res Commun       Date:  1999-05-27       Impact factor: 3.575

Review 5.  Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway.

Authors:  Cristen Pantano; Niki L Reynaert; Albert van der Vliet; Yvonne M W Janssen-Heininger
Journal:  Antioxid Redox Signal       Date:  2006 Sep-Oct       Impact factor: 8.401

6.  IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.

Authors:  Shin Maeda; Hideaki Kamata; Jun-Li Luo; Hyam Leffert; Michael Karin
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

7.  Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB.

Authors:  Y Sato; J Kato; R Takimoto; K Takada; Y Kawano; K Miyanishi; M Kobune; Y Sato; T Takayama; T Matunaga; Y Niitsu
Journal:  Gut       Date:  2006-03-31       Impact factor: 23.059

8.  Up-regulation of transforming growth factor alpha expression by transforming growth factor beta 1, epidermal growth factor, and N,N-dimethylformamide in human colon carcinoma cells.

Authors:  P A Zipfel; B L Ziober; S L Morris; K M Mulder
Journal:  Cell Growth Differ       Date:  1993-08

9.  Platelet-activating factor stimulates transcription of the heparin-binding epidermal growth factor-like growth factor in monocytes. Correlation with an increased kappa B binding activity.

Authors:  Z Pan; V V Kravchenko; R D Ye
Journal:  J Biol Chem       Date:  1995-04-07       Impact factor: 5.157

10.  Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates.

Authors:  A Sánchez; A M Alvarez; M Benito; I Fabregat
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

View more
  39 in total

1.  The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88.

Authors:  Istvan Hritz; Pranoti Mandrekar; Arumugam Velayudham; Donna Catalano; Angela Dolganiuc; Karen Kodys; Evelyn Kurt-Jones; Gyongyi Szabo
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

2.  Protein-tyrosine phosphatase 1B (PTP1B) deficiency confers resistance to transforming growth factor-β (TGF-β)-induced suppressor effects in hepatocytes.

Authors:  Conrad Ortiz; Laia Caja; Esther Bertran; Águeda Gonzalez-Rodriguez; Ángela M Valverde; Isabel Fabregat; Patricia Sancho
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

3.  NADPH oxidase NOX1 controls autocrine growth of liver tumor cells through up-regulation of the epidermal growth factor receptor pathway.

Authors:  Patricia Sancho; Isabel Fabregat
Journal:  J Biol Chem       Date:  2010-06-04       Impact factor: 5.157

4.  TGFβ1 rapidly activates Src through a non-canonical redox signaling mechanism.

Authors:  Hongqiao Zhang; Kelvin J A Davies; Henry Jay Forman
Journal:  Arch Biochem Biophys       Date:  2015-01-10       Impact factor: 4.013

5.  Mitochondrial permeability transition in rat hepatocytes after anoxia/reoxygenation: role of Ca2+-dependent mitochondrial formation of reactive oxygen species.

Authors:  Jae-Sung Kim; Jin-Hee Wang; John J Lemasters
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-01-12       Impact factor: 4.052

Review 6.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

7.  AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease.

Authors:  Weijing Cai; Massimo Torreggiani; Li Zhu; Xue Chen; John Cijiang He; Gary E Striker; Helen Vlassara
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-02       Impact factor: 4.249

8.  ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice.

Authors:  Bridget M Ford; Assaad A Eid; Monika Göőz; Jeffrey L Barnes; Yves C Gorin; Hanna E Abboud
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-15

Review 9.  Genetically modified animal models recapitulating molecular events altered in human hepatocarcinogenesis.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

10.  Protein modifications as potential biomarkers in breast cancer.

Authors:  Hongjun Jin; Richard C Zangar
Journal:  Biomark Insights       Date:  2009-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.